Notable
TEV-53408 · Vitiligo
Enrollment reopened
Teva Branded Pharmaceutical Products R&D LLCPhase 1 NCT06625177 Registry history of NCT06625177 on ClinicalTrials.gov (opens the registry)
5 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 4 with minor changes only.
Enrollment reopened
Teva Branded Pharmaceutical Products R&D LLCPhase 1 NCT06625177 Registry history of NCT06625177 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 19, 2026 to Nov 2, 2026; Final enrollment: 649 participants (planned 724)
Teva Branded Pharmaceutical Products R&D LLCPhase 3 NCT06664619 Registry history of NCT06664619 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Teva Branded Pharmaceutical Products R&D LLCPhase 2 NCT06568237 Registry history of NCT06568237 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 36 → 40 locations
Teva Branded Pharmaceutical Products R&D LLCPhase 2 NCT07197866 Registry history of NCT07197866 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Mar 8, 2031 to Jan 31, 2027
Teva Branded Pharmaceutical Products R&D LLCPhase 2 NCT05668013 Registry history of NCT05668013 on ClinicalTrials.gov (opens the registry)
| Phase 1 | 3 | |
| Phase 2 | 4 | |
| Phase 3 | 2 |
Asthma (2) · Crohn's Disease (1) · Ulcerative Colitis (1)